The studies, released by Johnson & Johnson, come as the U.S. gears up next month to offer a third dose for those who received the Pfizer and Moderna vaccines. The Johnson & Johnson announcement said studies showed a booster dose of its vaccine showed "a rapid and robust increase in spike-binding antibodies, ninefold higher than 28 days after the primary single-dose vaccination." The company said it was working with federal officials, including the Food and Drug Administration and Centers for Disease Control and Prevention, on next steps to boost the effects of the vaccine and ready a possible booster shot. The announcement came as CDC studies show vaccines are less effective against delta and a heightened need for such booster shots, though vaccines still were crucial in preventing hospitalizations. #JohnsonandJohnson #COVID #vaccines #pandemic